NEW YORK (GenomeWeb) – CareDx announced this week that it has closed its acquisition of Allenex. The acquisition included a successful tender of 98.37 percent of Allenex shares as part of a public tender offer concluded in Sweden, the company said. CareDx will be able to buy out the remaining shares on a compulsory basis. The company said last week that Allenex shareholders representing about 98 percent of the company's shares had accepted CareDx's takeover offer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.